{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:48:27Z","timestamp":1789541307047,"version":"build-2803163510"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.coviro.2018.04.002","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T13:30:39Z","timestamp":1525527039000},"page":"48-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Viral envelope-specific antibodies in chronic hepatitis B virus infection"],"prefix":"10.1016","volume":"30","author":[{"given":"Davide","family":"Corti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Benigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0512-6513","authenticated-orcid":false,"given":"Daniel","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2018.04.002_bib0525","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/1743-422X-10-239","article-title":"Medical virology of hepatitis B: how it began and where we are now","volume":"10","author":"Gerlich","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.coviro.2018.04.002_bib0530","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/hyb.2011.0052","article-title":"Monoclonal antibodies specific for hepatitis B e antigen and hepatitis B core antigen","volume":"30","author":"Sogut","year":"2011","journal-title":"Hybridoma (Larchmt)"},{"key":"10.1016\/j.coviro.2018.04.002_bib0535","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF01310576","article-title":"The affinities of monoclonal antibodies against core antigen of hepatitis B virus","volume":"134","author":"Apsalons","year":"1994","journal-title":"Arch Virol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0540","first-page":"16","article-title":"A large-scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies","author":"Xiang","year":"2017","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.coviro.2018.04.002_bib0545","doi-asserted-by":"crossref","first-page":"16760","DOI":"10.1074\/jbc.M117.802272","article-title":"Chimeric rabbit\/human Fab antibodies against the hepatitis Be-antigen and their potential applications in assays, characterization, and therapy","volume":"292","author":"Zhuang","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2018.04.002_bib0550","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jbiotec.2007.02.027","article-title":"Monoclonal antibody against non-dominant epitopes of HBV e Ag was raised by antigen-antibody co-immunization","volume":"129","author":"Yan","year":"2007","journal-title":"J Biotechnol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0555","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/hep.26125","article-title":"A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant","volume":"57","author":"Sureau","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.04.002_bib0560","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.1128\/JVI.77.16.8882-8892.2003","article-title":"Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions","volume":"77","author":"Schilling","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0565","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/hep.23778","article-title":"Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells","volume":"52","author":"Neumann","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.04.002_bib0570","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"elife"},{"key":"10.1016\/j.coviro.2018.04.002_bib0575","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.04.002_bib0580","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.coviro.2018.04.002_bib0585","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2018.04.002_bib0590","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1073\/pnas.79.2.650","article-title":"Selecting binding and complement-mediated lysis of human hepatoma cells (PLC\/PRF\/5) in culture by monoclonal antibodies to hepatitis B surface antigen","volume":"79","author":"Shouval","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2018.04.002_bib0595","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/298567a0","article-title":"Immunotherapy in nude mice of human hepatoma using monoclonal antibodies against hepatitis B virus","volume":"298","author":"Shouval","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2018.04.002_sbref0600","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/gutjnl-2014-308964","article-title":"Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen","volume":"65","author":"Zhang","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2018.04.002_sbref0605","doi-asserted-by":"crossref","first-page":"213","DOI":"10.7554\/eLife.26738","article-title":"A potent human neutralizing antibody Fc-dependently reduces established HBV infections","volume":"6","author":"Li","year":"2017","journal-title":"elife"},{"key":"10.1016\/j.coviro.2018.04.002_bib0610","doi-asserted-by":"crossref","first-page":"8766","DOI":"10.1073\/pnas.1003854107","article-title":"B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure","volume":"107","author":"Farci","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.coviro.2018.04.002_bib0615","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nm.2262","article-title":"Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes","volume":"17","author":"Monsalvo","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2018.04.002_bib0620","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.15252\/emmm.201606593","article-title":"Immunoregulatory functions of immune complexes in vaccine and therapy","volume":"8","author":"Wen","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.coviro.2018.04.002_bib0625","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1126\/science.6231724","article-title":"Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen","volume":"224","author":"Celis","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.coviro.2018.04.002_sbref0630","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.4049\/jimmunol.1502061","article-title":"Clearing persistent extracellular antigen of hepatitis B virus: an immunomodulatory strategy to reverse tolerance for an effective therapeutic vaccination","volume":"196","author":"Zhu","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0635","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0016-5085(87)90427-6","article-title":"Frequency and significance of concurrent hepatitis B surface antigen and antibody in acute and chronic hepatitis B","volume":"93","author":"Shiels","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.04.002_bib0640","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jhep.2013.11.004","article-title":"N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape","volume":"60","author":"Yu","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0645","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jhep.2013.12.001","article-title":"Chance and necessity of simultaneous HBsAg and anti-HBs detection in the serum of chronic HBsAg carriers","volume":"60","author":"Brunetto","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0650","article-title":"Mapping HBsAg epitope profiles to predict HBsAg loss\/seroconversion in a treatment naive cohort of genotype A chronic hepatitis B (CHB) patients receiving tenofovir disoproxil fumarate (TDF) therapy","author":"Walsh","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.04.002_bib0655","doi-asserted-by":"crossref","first-page":"S602","DOI":"10.1016\/S0168-8278(16)01112-0","article-title":"Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAI) therapy Based on HBsAg epitope profile analysis","volume":"64","author":"Walsh","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0660","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0665","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.4049\/jimmunol.1103139","article-title":"IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection","volume":"189","author":"Das","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0670","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12967-014-0251-9","article-title":"Increased numbers of CD5+CD19+CD1dhighIL-10+ Bregs, CD4+Foxp3+ Tregs, CD4+CXCR5+Foxp3+ follicular regulatory T (TFR) cells in CHB or CHC patients","volume":"12","author":"Wang","year":"2014","journal-title":"J Transl Med"},{"key":"10.1016\/j.coviro.2018.04.002_bib0675","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/mmr.2017.6605","article-title":"Regulatory B cells in infectious disease (Review)","volume":"16","author":"Dai","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.coviro.2018.04.002_sbref0680","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1172\/JCI85113","article-title":"Human regulatory B cells in health and disease: therapeutic potential","volume":"127","author":"Mauri","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2018.04.002_bib0685","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0033-1345722","article-title":"Immunosuppression and HBV reactivation","volume":"33","author":"Shouval","year":"2013","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.coviro.2018.04.002_bib0690","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study","volume":"32","author":"Seto","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0695","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00535-010-0331-4","article-title":"Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy","volume":"46","author":"Kusumoto","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0700","doi-asserted-by":"crossref","DOI":"10.1038\/ni.2746","article-title":"The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-\u03b21 production and FcRL4 expression","author":"Jelicic","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0705","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/COH.0000000000000092","article-title":"B-cell exhaustion in HIV infection: the role of immune activation","volume":"9","author":"Moir","year":"2014","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.coviro.2018.04.002_bib0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2017.07.003","article-title":"Atypical memory B cells in human chronic infectious diseases: an interim report","author":"Portugal","year":"2017","journal-title":"Cell Immunol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0715","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20121970","article-title":"Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies","author":"Muellenbeck","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2018.04.002_bib0720","first-page":"4741","volume":"188","author":"Wilson","year":"2012","journal-title":"Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG"},{"key":"10.1016\/j.coviro.2018.04.002_bib0725","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.coi.2017.03.004","article-title":"An antigen to remember: regulation of B cell memory in health and disease","volume":"45","author":"Pupovac","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coviro.2018.04.002_sbref0730","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fimmu.2017.00966","article-title":"Chronic exposure to malaria is associated with inhibitory and activation markers on atypical memory B cells and marginal zone-like B cells","volume":"8","author":"Ubillos","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2018.04.002_sbref0735","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cellimm.2017.05.008","article-title":"Role of CD11c+ T-bet+ B cells in human health and disease","volume":"321","author":"Karnell","year":"2017","journal-title":"Cell Immunol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0740","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1172\/JCI116497","article-title":"The serology of chronic hepatitis B infection revisited","volume":"91","author":"Maruyama","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2018.04.002_bib0745","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jhep.2010.10.016","article-title":"Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections","volume":"55","author":"Oliviero","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0750","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/cmi.2015.25","article-title":"Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients","volume":"12","author":"Xu","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0755","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27805","article-title":"Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells","volume":"62","author":"Vanwolleghem","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.04.002_bib0760","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1365-2249.1996.d01-732.x","article-title":"Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection","volume":"105","author":"B\u00f6cher","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0765","doi-asserted-by":"crossref","first-page":"16993","DOI":"10.1073\/pnas.1306437110","article-title":"Liver type I regulatory T cells suppress germinal center formation in HBV-tolerant mice","volume":"110","author":"Xu","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.coviro.2018.04.002_bib0770","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/hep.26489","article-title":"Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection","volume":"58","author":"Li","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.04.002_bib0775","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.04.002_bib0780","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0168-8278(94)80015-4","article-title":"Enhancement of HBsAg detection in serum of patients with chronic liver disease following removal of circulating immune complexes","volume":"20","author":"Ackerman","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0785","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1086\/513296","article-title":"The enigma of concurrent hepatitis B surface antigen (HBsAg) and antibodies to HBsAg","volume":"44","author":"Gerlich","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2018.04.002_bib0790","first-page":"493","article-title":"Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus","volume":"84","author":"Madalinski","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0795","first-page":"371","article-title":"HBsAg immune complexes in the course of infection with hepatitis B virus","volume":"36","author":"Madalinski","year":"1979","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0800","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41598-017-00694-8","article-title":"Evolution of full-length genomes of HBV quasispecies in sera of patients with a coexistence of HBsAg and anti-HBs antibodies","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2018.04.002_bib0805","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1128\/JVI.80.6.2968-2975.2006","article-title":"Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of \u201ca\u201d determinant variants","volume":"80","author":"Lada","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0810","doi-asserted-by":"crossref","first-page":"S771","DOI":"10.1093\/infdis\/jix355","article-title":"Toward a cure for hepatitis B virus infection: combination therapy involving viral suppression and immune modulation and long-term outcome","volume":"216","author":"Wu","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.04.002_bib0815","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/JCM.00726-13","article-title":"Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance","volume":"51","author":"Shinkai","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0820","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1128\/JCM.30.5.1111-1119.1992","article-title":"New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection","volume":"30","author":"Zoulim","year":"1992","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0825","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.vaccine.2009.10.023","article-title":"Anti-preS responses influence the anti-HBs response in newborns after vaccination with the third generation Sci-B-Vac vaccine","volume":"28","author":"Sylvan","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.04.002_bib0830","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp1802256","article-title":"Monoclonal antibodies for emerging infectious diseases\u2014borrowing from history","author":"Marston","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2018.04.002_bib0835","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1053\/jhep.2000.19789","article-title":"Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review","volume":"32","author":"Shouval","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.04.002_bib0840","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0140-6736(81)90832-1","article-title":"Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial","volume":"2","author":"Beasley","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2018.04.002_bib0845","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0140-6736(88)90541-7","article-title":"Hepatitis B variant in Europe","volume":"2","author":"Zanetti","year":"1988","journal-title":"The Lancet"},{"key":"10.1016\/j.coviro.2018.04.002_bib0850","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0140-6736(90)91874-A","article-title":"Vaccine-induced escape mutant of hepatitis B virus","volume":"336","author":"Carman","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2018.04.002_bib0855","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hep.510300309","article-title":"Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus","volume":"30","author":"Ogata","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.04.002_bib0860","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00234-14","article-title":"Commonly found variations\/mutations in the HBsAg of hepatitis B virus in the context of effective immunization programs: questionable clinical and public health significance","volume":"88","author":"Locarnini","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.04.002_sbref0865","first-page":"1","article-title":"Antibody-mediated immunotherapy against chronic hepatitis B virus infection","volume":"0","author":"Gao","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.coviro.2018.04.002_bib0870","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.antiviral.2015.06.002","article-title":"NTCP opens the door for hepatitis B virus infection","volume":"121","author":"Yan","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.04.002_bib0875","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/jmv.1890160112","article-title":"Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: an experimental study in the chimpanzee","volume":"16","author":"Iwarson","year":"1985","journal-title":"J Med Virol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0880","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.antiviral.2008.03.006","article-title":"Neutralization of hepatitis B virus (HBV) by human monoclonal antibody against HBV surface antigen (HBsAg) in chimpanzees","volume":"79","author":"Kim","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.04.002_bib0885","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/0140-6736(90)93069-2","article-title":"Monoclonal antibody to HBsAg for chronic hepatitis B virus infection with hypogammaglobulinaemia","volume":"335","author":"Lever","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2018.04.002_bib0890","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1034\/j.1600-0676.2001.021003207.x","article-title":"Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients","volume":"21","author":"van Nunen","year":"2001","journal-title":"Liver"},{"key":"10.1016\/j.coviro.2018.04.002_bib0895","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1053\/jhep.2000.9632","article-title":"Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees","volume":"32","author":"Eren","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.04.002_bib0900","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/jhep.2002.31867","article-title":"Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties","volume":"35","author":"Galun","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.04.002_bib0905","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(73)93321-7","article-title":"Infusion of hepatitis-B antibody in antigen-positive active chronic hepatitis","volume":"2","author":"Reed","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2018.04.002_bib0910","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00535-016-1189-x","article-title":"Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection","volume":"51","author":"Tsuge","year":"2016","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.coviro.2018.04.002_sbref0915","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/gutjnl-2016-312162","article-title":"Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo","volume":"67","author":"Allweiss","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2018.04.002_sbref0920","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s13238-017-0438-y","article-title":"A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys","volume":"9","author":"Kang","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.coviro.2018.04.002_bib0925","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/imr.12392","article-title":"Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation","volume":"270","author":"Igawa","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coviro.2018.04.002_bib0930","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1600-6143.2006.01636.x","article-title":"Efficacy of a Pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B","volume":"7","author":"Lo","year":"2007","journal-title":"Am J Transpl"},{"key":"10.1016\/j.coviro.2018.04.002_bib0935","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1016\/j.vaccine.2008.09.056","article-title":"The global impact of vaccination against hepatitis B: a historical overview","volume":"26","author":"Zanetti","year":"2008","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1016\/j.coviro.2018.04.002_bib0940","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S0168-8278(03)00152-1","article-title":"Hepatitis B vaccines","volume":"39","author":"Shouval","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0945","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00430-014-0374-x","article-title":"Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1\/Pre-S2\/S vaccine","volume":"204","author":"Shouval","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0950","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1586\/14760584.1.2.141","article-title":"Recombinant hepatitis B triple antigen vaccine: hepacare","volume":"1","author":"Zuckerman","year":"2002","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2018.04.002_bib0955","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0168-8278(01)00028-9","article-title":"Efficacy and limitations of a specific immunotherapy in chronic hepatitis B","volume":"34","author":"Pol","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2018.04.002_bib0960","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/infdis\/jiv748","article-title":"Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose","volume":"214","author":"Bruce","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.04.002_bib0965","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1086\/314578","article-title":"What level of hepatitis B antibody is protective?","volume":"179","author":"Jack","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.04.002_bib0970","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1053\/j.gastro.2013.07.044","article-title":"The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity","volume":"145","author":"Werner","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2018.04.002_bib0975","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/infdis\/jiv348","article-title":"CD4+ T cells are not required for suppression of hepatitis B virus replication in the liver of vaccinated chimpanzees","volume":"213","author":"Rybczynska","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.04.002_bib0980","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.vaccine.2006.01.007","article-title":"Comparative immunogenicity of a PreS\/S hepatitis B vaccine in non- and low responders to conventional vaccine","volume":"24","author":"Rendi-Wagner","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.04.002_bib0985","doi-asserted-by":"crossref","first-page":"a021451","DOI":"10.1101\/cshperspect.a021451","article-title":"The Woodchuck, a nonprimate model for immunopathogenesis and therapeutic immunomodulation in chronic hepatitis B virus infection","volume":"5","author":"Roggendorf","year":"2015","journal-title":"Cold Spring Harbor Persp Med"},{"key":"10.1016\/j.coviro.2018.04.002_bib0990","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.virol.2003.09.014","article-title":"In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees","volume":"318","author":"Hong","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2018.04.002_bib0995","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.4014\/jmb.1703.03066","article-title":"Construction and characterization of an anti-hepatitis B virus preS1 humanized antibody that binds to the essential receptor binding site","volume":"27","author":"Wi","year":"2017","journal-title":"J Microbiol Biotechnol"},{"key":"10.1016\/j.coviro.2018.04.002_bib1000","doi-asserted-by":"crossref","DOI":"10.1038\/srep21240","article-title":"Inhibition of preS1\u2013hepatocyte interaction by an array of recombinant human antibodies from naturally recovered individuals","author":"Sankhyan","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2018.04.002_bib1005","doi-asserted-by":"crossref","first-page":"9214","DOI":"10.1073\/pnas.0603316103","article-title":"Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2018.04.002_bib1010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2005.06.012","article-title":"Hepatitis B virus-neutralizing anti-Pre-S1 human antibody fragments from large na\u00efve antibody phage library","volume":"68","author":"Park","year":"2005","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.04.002_bib1015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0161-5890(99)00074-7","article-title":"Characterization of neutralizing anti-Pre-S1 and anti-Pre-S2 (HBV) monoclonal antibodies and their fragments","volume":"36","author":"K\u00fcttner","year":"1999","journal-title":"Mol Immunol"},{"key":"10.1016\/j.coviro.2018.04.002_bib1020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/jmv.1068","article-title":"Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes","volume":"64","author":"Heijtink","year":"2001","journal-title":"J Med Virol"},{"key":"10.1016\/j.coviro.2018.04.002_bib1025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.antiviral.2007.01.005","article-title":"Human monoclonal antibody against Hepatitis B virus surface antigen (HBsAg)","volume":"75","author":"Shin","year":"2007","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.04.002_bib1030","doi-asserted-by":"crossref","first-page":"e0125704","DOI":"10.1371\/journal.pone.0125704","article-title":"A human monoclonal antibody against hepatitis B surface antigen with potent neutralizing activity","volume":"10","author":"Cerino","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2018.04.002_bib1035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2017.06.013","article-title":"Construction of a hepatitis B virus neutralizing chimeric monoclonal antibody recognizing escape mutants of the viral surface antigen (HBsAg)","volume":"144","author":"Golsaz Shirazi","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.04.002_bib1040","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J Hepatol"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625718300397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625718300397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T16:37:45Z","timestamp":1604248665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625718300397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":104,"alternative-id":["S1879625718300397"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2018.04.002","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral envelope-specific antibodies in chronic hepatitis B virus infection","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2018.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}